Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2020-08-30 Governance Information
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Appendix 4G 11 pages 229.9KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G' and is described as a 'Key to Disclosures Corporate Governance Council Principles and Recommendations' for Imugene Limited for the financial year ended 30 June 2020. It references compliance with ASX Listing Rules 4.7.3 and 4.10.3, which require lodging a corporate governance statement alongside the annual report. The document contains detailed disclosures about corporate governance practices, board structure, committee charters, and compliance with governance principles. It is not the annual report itself but a governance disclosure appendix related to the annual report. The document is lengthy (15,000 characters) and contains substantive governance information, not just an announcement or a brief summary. Given the focus on corporate governance disclosures and the detailed nature of the content, the most appropriate classification is Governance Information (CGR).
2020-08-30 English
Proposed issue of Securities - IMU 5 pages 28.0KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Proposed issue of securities' and contains detailed information about a new announcement regarding a placement or other type of securities issue by Imugene Limited. It includes specifics such as the number of securities to be issued, issue price, approval requirements, and other related details. There is no financial performance data, earnings information, or management discussion. The content clearly relates to a capital raising or financing activity. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2020-08-24 English
Appendix 2A 15 pages 795.4KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the securities to be quoted, and references to previous announcements such as Appendix 3B. This form is a regulatory filing used to notify the exchange about new securities being quoted, typically following a capital raising or issuance event. It is not a financial report, earnings release, or management discussion, nor is it a proxy or voting result announcement. The document is a formal regulatory announcement related to capital markets compliance and securities quotation. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-08-24 English
Imugene Receives Third PD1-VAXX Ethics Trial Approval 2 pages 124.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited about receiving ethics approval to start a Phase I clinical trial for a new cancer immunotherapy. It discusses clinical trial approvals, patient screening, and study details. There is no financial data, no mention of annual or quarterly reports, no earnings information, no management changes, no voting results, and no regulatory certifications. The content is a corporate announcement about clinical trial progress, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other specific categories.
2020-08-20 English
Proposed issue of Securities - IMU 5 pages 28.1KB
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a proposed issue of securities by Imugene Limited. It details the number of securities to be issued, the issue price, the class of securities, and compliance with ASX listing rules. There is no financial performance data, management discussion, or audit information. The content focuses on the capital raising activity and issuance of new shares. This fits the definition of a Capital/Financing Update (CAP). The document length is about 5747 characters, which is consistent with a detailed announcement but not a full financial report. Therefore, the appropriate classification is CAP with high confidence.
2020-08-17 English
Appendix 2A 15 pages 796.8KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the securities to be quoted, and references to previous announcements such as Appendix 3B. The document is regulatory in nature, related to the listing and quotation of securities, and does not contain financial statements, earnings data, or management discussion. It is not an announcement of a report but a formal application form for securities quotation. This type of document fits best under the category of Regulatory Filings (RNS), as it is a compliance and disclosure document required by the exchange but does not fall under other specific categories like capital updates or earnings releases.
2020-08-17 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.